Related Experiment Videos
Extracellular UTP stimulates electrogenic bicarbonate secretion across CFTR knockout gallbladder epithelium
L L Clarke1, M C Harline, L R Gawenis
1Dalton Cardiovascular Research Center and Departments of Veterinary Biomedical Sciences, University of Missouri-Columbia, 65211, USA. ClarkeL@missouri.edu
Summary
P2Y(2) receptor agonists like UTP can stimulate bicarbonate secretion in cystic fibrosis (CF) gallbladder, bypassing the defective CFTR channel. This finding offers potential therapeutic strategies for CF-related pancreatic and biliary diseases.
Area of Science:
- Physiology
- Gastroenterology
- Cell Biology
Background:
- Cystic fibrosis (CF) involves impaired CFTR-mediated secretion, leading to pancreatic and biliary issues.
- P2Y(2) receptor agonists are explored to bypass CFTR defects by stimulating chloride secretion.
- The effect of these agonists on bicarbonate secretion in CF remains unclear.
Purpose of the Study:
- To investigate the role of P2Y(2) receptor agonists in stimulating transepithelial bicarbonate secretion.
- To determine the mechanism of anion conductance activated by P2Y(2) receptors in CF gallbladder.
Main Methods:
- Ussing chamber studies on gallbladder mucosa from CFTR knockout mice.
- Activation of luminal P2Y(2) receptors using UTP.
- Measurement of short-circuit current (I(sc)) and bicarbonate flux (J(s-->m)) under various ionic conditions and with inhibitors (DIDS, bumetanide).
Main Results:
- UTP induced a sustained, Cl(-) independent, HCO(3)(-) dependent plateau in I(sc).
- UTP increased both I(sc) and HCO(3)(-) secretion (J(s-->m)) in pH stat studies.
- The UTP-induced response was insensitive to bumetanide but blocked by luminal DIDS, indicating Ca(2+)-dependent anion conductance.
Conclusions:
- P2Y(2) receptor activation stimulates electrogenic bicarbonate secretion in CF gallbladder.
- This secretion is mediated by an intracellular Ca(2+)-dependent anion conductance, independent of CFTR.
- P2Y(2) agonists represent a potential therapeutic avenue for CF-related digestive diseases.